In addition, a phase 3 study of pyrotinib versus placebo after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (NCT03980054) is being conducted to investigate whether the positive results in the neoadjuvant setting would be substantiated in the adjuvant setting in terms of invasive DFS. Here, ERBB2 is linked to breast cancer.